TransCONFIRM: Identification of a genetic signature of response to fulvestrant in advanced hormone receptor positive breast cancer

PURPOSE: Fulvestrant is an estrogen receptor (ER) antagonist and an approved treatment for metastatic estrogen receptor positive (ER+) breast cancer. With the exception of ER levels, there are no established predictive biomarkers of response to single agent fulvestrant. We attempted to identify a ge...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Jeselsohn, Rinath, Barry, William T., Migliaccio, Ilenia, Biagioni, Chiara, Zhao, Jin, De Tribolet-Hardy, Jonas, Guarducci, Cristina, Bonechi, Martina, Laing, Naomi, Winer, Eric P., Brown, Myles, Di Leo, Angelo, Malorni, Luca
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5124409/
https://ncbi.nlm.nih.gov/pubmed/27185372
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0148
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars